New Haven, Conn.Yale School of Medicine researchers have received $8.4 million to study how cancer cells mend their own chromosomes and DNA after damage caused by radiation and chemotherapy.
The study funded by the National Institutes of Health (NIH) is the next step in developing targeted cancer therapies, said the lead researcher, Peter Glazer, M.D., chair of therapeutic radiology and leader of the radiobiology research program at Yale Cancer Center.
We have put together a program to target protein and DNA repair enzymes that fix the DNA, Glazer said. We feel this could create an Achilles heel for cancer cells that would make them more vulnerable to traditional cancer therapies.
Cancer therapies such as radiation and chemotherapy work by damaging the cancer cells DNA, which carries the information, or blueprint, for cell replication.
Glazer said the four NIH funded Yale studies combine basic and translational research and may lead to new therapies for use with conventional radiation and chemotherapy.
It is our hope to be able to offer novel therapies derived from this research to our patients at the Yale Cancer Center, he said. The overall program represents a significant commitment of the Yale School of Medicine and the participating investigators to studies that have direct relevance to cancer biology and therapy.
In one research project, Alan Sartorelli, professor of pharmacology, will develop new cancer prodrugs that become activated in the low-oxygen conditions in which tumor cells can thrive. Once activated, the drug sets in motion the destruction of a resistance protein that repairs certain DNA lesions.
Glazer will lead a study of the cancer DNA repair genes, RAD51 and BRCA1, in cancer cells. His goal is to devise strategies to render cancer cells vulnerable to therapies that target interconnected repair pathways. RAD51 creates a protein that performs DNA repair and BRCA1 is a tu
'/>"/>
| Contact: Jacqueline Weaver jacqueline.weaver@yale.edu 203-432-8555 Yale University Source:Eurekalert |
Related biology news :
1. DuPonts first biologically derived polymer receives global recognition
2. OneWorld Health drug receives Orphan designation from U.S. and European regulatory agencies
3. Research on antibiotics receives historical recognition
4. Anthrax test, developed by army and CDC, receives FDA approval
5. Research team receives $7.5 million to study cassava
6. A comprehensive response to HIV could prevent 10 million AIDS deaths in Africa by 2020
7. UCLA launches $20 million stem cell institute to investigate HIV, cancer and neurological disorders
8. Six million Africans face famine because of locusts, drought
9. Retrovirus struck ancestors of chimpanzees and gorillas millions of years ago, but did not affect ancestral humans
10. Evidence of 600-million-year old fungi-algae symbiosis discovered in marine fossils
11. $5.1 billion would save 6 million children
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |